About immix biopharma inc - IMMX
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.
IMMX At a Glance
Immix Biopharma, Inc.
11400 West Olympic Boulevard
Los Angeles, California 90064
| Phone | 1-310-651-8041 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -29,438,613.00 | |
| Sector | Health Technology | Employees | 21 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
IMMX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.953 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.722 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.015 |
IMMX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,401,838.714 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IMMX Liquidity
| Current Ratio | 10.013 |
| Quick Ratio | 10.013 |
| Cash Ratio | 9.931 |
IMMX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -46.074 |
| Return on Equity | -55.001 |
| Return on Total Capital | -31.031 |
| Return on Invested Capital | -54.02 |
IMMX Capital Structure
| Total Debt to Total Equity | 1.144 |
| Total Debt to Total Capital | 1.131 |
| Total Debt to Total Assets | 1.023 |
| Long-Term Debt to Equity | 0.995 |
| Long-Term Debt to Total Capital | 0.984 |